Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Your BMI might not tell the full story about obesity, new research suggests

12

Nov 2026

Your BMI might not tell the full story about obesity, new research suggests

A study of 6,978 middle-aged UK adults found that nearly 69% of those classified as having obesity by BMI met the criteria for preclinical rather than clinical obesity under a new diagnostic framework. Clinical obesity was associated with higher five-year mortality odds, while conventional BMI categories showed no statistically significant associations, although the small number of deaths limits the strength of these findings.

A 43-gram sugar gap separates adults who check food labels from those who rarely do

12

Nov 2026

A 43-gram sugar gap separates adults who check food labels from those who rarely do

A nationally representative US study of 9,416 children and adults found that frequent nutrition label users consumed an average of 42.8 g less added sugar daily among adults and 14.5 g less among children compared with infrequent users. The findings suggest an association between checking nutrition labels and lower added sugar intake, although the observational study could not establish causation.

A 12-year study links longer TV viewing to faster kidney function decline

12

Nov 2026

A 12-year study links longer TV viewing to faster kidney function decline

A 12-year study of 6,220 Australian adults found that longer daily television viewing was associated with faster kidney function decline, with a stronger association among people with type 2 diabetes. Exploratory analyses suggested that women and physically inactive individuals may also be more affected, although some findings were inconsistent and the observational study could not establish causation.

A study of 844,000 adults reveals what BMI misses about obesity

12

Nov 2026

A study of 844,000 adults reveals what BMI misses about obesity

A multinational study of 844,108 adults found that combining BMI with waist measurements improved obesity classification and identified mortality risks that BMI alone could miss. Clinical obesity was associated with a 69% higher all-cause mortality hazard, compared with 19% for preclinical obesity, while most participants with preclinical obesity were not estimated to progress to clinical obesity during long-term follow-up.

Liver-derived protein helps protect brain cells and improves memory in Alzheimer's mice

12

Nov 2026

Liver-derived protein helps protect brain cells and improves memory in Alzheimer's mice

Researchers identified 92 circulating proteins that cross the blood-brain barrier and enter brain tissue, revealing how proteins such as liver-derived APOA1 help regulate astrocyte cholesterol metabolism and support neuronal synapses. In an Alzheimer's disease mouse model, APOA1 transport was impaired, but increasing its production in the liver reduced selected inflammatory and amyloid-related abnormalities, improved synaptic integrity, and enhanced some measures of memory.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.